Systematic analysis of 108 cannabis cultivars reveals beta-caryophyllene and myrcene as the most consistent terpenes. The analytical chemistry is solid; the therapeutic claims remain largely unproven in humans.
Anyone who wants to understand what terpenes cannabis actually contains — versus what the marketing claims — and whether the science supports shopping by terpene profile.
108 chemotypes analyzed — caryophyllene and myrcene dominate
The Backstory
By 2020, the cannabis industry had a terpene obsession. Dispensary menus listed terpene profiles alongside THC percentages. Products were marketed by dominant terpenes. Consumers were told that myrcene meant sedation, limonene meant energy, and linalool meant relaxation. The entourage effect — popularized by Russo's 2011 review — had been translated into a marketing doctrine: terpenes drive the cannabis experience.
But the actual science was thinner than the marketing implied. How much of each terpene does cannabis actually contain? Which terpenes appear consistently across cultivars, and which are rare? And what does the analytical chemistry say about whether these compounds exist in quantities sufficient to produce the effects they're credited with?
Lumír Hanuš — the Czech analytical chemist who had co-discovered anandamide in 1992 and reported noladin ether in 2001 — turned his GC-MS expertise to a question that the industry was answering with confidence but science was answering with shrugs: are terpenes in cannabis actually important?
The Analytical Approach
This wasn't a theoretical review like Russo's. Hanuš and his colleague Yotam Hod at Lumir Lab in Jerusalem took the analytical chemistry approach: measure what's actually there.
How They Did It
How They Characterized Cannabis Terpenes
Collect samples
108 different cannabis chemotypes were analyzed — a large and diverse sample set covering the range of commercially and medicinally relevant cultivars.
Both cannabis inflorescences and essential oils were examined
GC-MS analysis
Gas chromatography-mass spectrometry: the gold standard for identifying and quantifying volatile compounds. Each sample was vaporized, separated by molecular properties, and identified against known reference standards.
GC-MS provides both identity (which terpenes) and relative abundance (how much)
Catalog terpene profiles
For each chemotype, the researchers identified the top 10 terpenes by relative abundance. They tracked which terpenes appeared most consistently across all 108 samples.
This produced a dataset showing not just what's possible in cannabis, but what's typical
Review biological activity
For each major terpene identified, the existing pharmacological literature was reviewed — documented effects in animal models, in vitro studies, and the limited human data available.
Bridging the gap between what's in the plant and what it might do biologically
Hanuš & Hod (2020), Med Cannabis Cannabinoids 3:25-60
What's Actually in the Plant
The most important finding was empirical: which terpenes dominate cannabis consistently, across dozens of cultivars.
Beta-caryophyllene and beta-myrcene
were the two most prevalent terpenes across all 108 chemotypes analyzed. Both appeared in the top 10 terpenes in over 80 samples each. This makes them the backbone of the cannabis terpene profile — the two compounds most likely to be present in meaningful concentrations regardless of the specific cultivar.
Other common terpenes — alpha-pinene, limonene, beta-pinene, linalool — appeared frequently but with more variation between chemotypes.
Hanuš & Hod (2020), Med Cannabis Cannabinoids 3:25-60
The dominance of beta-caryophyllene is significant because it is the only terpene proven to directly bind a cannabinoid receptor. It's a selective CB2 agonist — confirmed by Gertsch et al. in 2008 — making it both a terpene and a functional cannabinoid. If any terpene in cannabis contributes to the entourage effect through direct receptor interaction, beta-caryophyllene is the strongest candidate.
The dominance of myrcene matters for a different reason. Myrcene is the terpene most associated with sedation in popular cannabis culture — the "couch lock" molecule. It's analgesic, anti-inflammatory, and a muscle relaxant in animal models. Its consistent prevalence across cultivars means it's the terpene most consumers are actually exposed to in meaningful amounts.
The Six That Matter Most
Process
Major Cannabis Terpenes by Prevalence and Pharmacology
Beta-Caryophyllene
Most prevalent terpene across 108 chemotypes. Spicy, peppery aroma. The only terpene that directly binds CB2 cannabinoid receptors. Gastroprotective, analgesic, anticancerogenic, antifungal, antibacterial, antidepressant, anti-inflammatory. FDA-approved food additive.
Beta-Myrcene
Second most prevalent. Earthy, musky, herbal aroma. Antipsychotic, antioxidant, analgesic, anti-inflammatory, sedative, muscle relaxant in animal models. The most abundant monoterpene in many cannabis strains.
Alpha-Pinene
Pine aroma. The most widely occurring terpenoid in nature (not just cannabis). Antibacterial, anti-inflammatory, bronchodilator. Acetylcholinesterase inhibitor — may counteract THC-induced memory impairment.
Limonene
Citrus aroma. Anxiolytic, antidepressant in animal models. Enhances absorption of other compounds through skin and mucous membranes. Immune-stimulating.
Linalool
Floral, lavender aroma. Anxiolytic, sedative, anticonvulsant, analgesic. Local anesthetic properties. Long history of use in aromatherapy.
Alpha-Humulene
Earthy, woody aroma. Anti-inflammatory, anorectic (appetite-suppressing). Closely related to beta-caryophyllene structurally. Often co-occurs with caryophyllene.
Hanuš & Hod (2020), Med Cannabis Cannabinoids 3:25-60
The Honest Assessment
Hanuš and Hod reviewed the biological activity literature for each terpene and arrived at a nuanced conclusion: terpenes are pharmacologically active, probably therapeutically important, and insufficiently studied.
What the Data Supports
moderate- Cannabis consistently contains terpenes in quantifiable amounts, with beta-caryophyllene and myrcene dominating most cultivars
- Individual terpenes have well-documented pharmacological effects in preclinical studies (animal models, cell cultures)
- Beta-caryophyllene is a confirmed CB2 receptor agonist — a terpene that is functionally a cannabinoid
- Terpenes are GRAS-designated (FDA Generally Recognized as Safe) food additives with established safety profiles
- The authors conclude that 'all components of the cannabis plant likely exert some therapeutic effect, more than any single compound alone'
What Remains Unproven
moderate- Only beta-caryophyllene has demonstrated direct cannabinoid receptor interaction — other terpenes' mechanisms are through non-ECS pathways
- The authors acknowledge that Santiago/Finlay et al. (2020) found 'the putative entourage effect cannot be explained by direct effects at CB1 or CB2'
- Relative percentages from GC-MS don't reflect absolute quantities absorbed by a user — the gap between 'present in the plant' and 'active in the body' is significant
- Only a few terpenes have pharmacology studied sufficiently for human therapeutic conclusions
- No human clinical trial has tested specific terpene-cannabinoid combinations vs controls
Hanuš & Hod (2020); Santiago et al. (2020), Front Pharmacol
The paper's title asks a question: "Are they important?" The authors' answer is qualified: probably yes, but we don't have enough human data to say definitively. The analytical chemistry shows terpenes are consistently present. The preclinical pharmacology shows they're biologically active. The clinical evidence for their role in the cannabis experience remains largely theoretical.
What This Means for Consumers
Myth vs. Reality
You should choose cannabis products based primarily on their terpene profile because terpenes determine the experience.
Terpene profiles provide useful information about aroma and flavor, and they may contribute to effects, but the evidence that specific terpenes reliably predict specific experiences is weak. THC and CBD content, the THC:CBD ratio, dose, route of administration, and individual biology are far more established predictors of cannabis effects than terpene profiles. Using terpene data to find products you enjoy is reasonable — using it to predict specific therapeutic outcomes is premature.
The Evidence
Hanuš & Hod (2020) documented significant terpene variation across 108 chemotypes but noted that 'only few studies have pharmacology' sufficient for therapeutic conclusions in humans. Santiago et al. (2020) found no terpene activity at CB1/CB2. No clinical trial has validated terpene-based product selection.
Hanuš & Hod (2020), Med Cannabis Cannabinoids 3:25-60
The practical takeaway: terpenes are real compounds with real pharmacology, but the cannabis industry has outpaced the science in its claims about what they do. Beta-caryophyllene's CB2 activity is confirmed. Everything else is promising preclinical data that hasn't been validated in humans. For a full guide to what the science supports, see our article on terpenes explained.
Hanuš: The Analyst Returns
Lumír Hanuš was 77 years old when this paper was published. His career had traced an extraordinary arc through cannabinoid science — from co-discovering the first endocannabinoid in 1992 to reporting a disputed third endocannabinoid in 2001, and now to systematically cataloging the terpene chemistry of 108 cannabis cultivars.
Throughout, his contribution was always the same: precise analytical chemistry. Hanuš was the person who could extract, purify, and identify vanishingly small quantities of bioactive molecules from complex biological mixtures. The technique that found anandamide in pig brain worked just as well for finding beta-caryophyllene in cannabis flowers.
His lab, Lumir Lab (named after himself), was based at the Hebrew University Biotechnology Park — the same campus where he had worked with Raphael Mechoulam for three decades. By 2020, his focus had shifted from discovery to characterization: not finding new molecules, but rigorously documenting what the cannabis plant actually contains and what those contents might do.
Research Timeline
The Terpene Question: From Marketing to Science
Ben-Shabat & Mechoulam coin 'entourage effect'
The concept that inactive compounds enhance active ones — originally about endogenous lipids, not terpenes
Gertsch et al. confirm beta-caryophyllene as CB2 agonist
The first (and still only) terpene proven to directly bind a cannabinoid receptor
Russo's 'Taming THC' review
Maps theoretical terpene-cannabinoid synergies — the paper that launched industry terpene marketing
Hanuš & Hod publish terpene characterization
Systematic GC-MS analysis of 108 chemotypes: beta-caryophyllene and myrcene dominate most cultivars
Santiago/Finlay et al. find no terpene activity at CB1/CB2
Five major terpenes did not activate cannabinoid receptors — challenging the entourage mechanism
LaVigne et al. find terpenes ARE cannabimimetic
Contradictory finding: terpenes produce cannabinoid-like effects in mice via CB1 and A2a receptors
Multiple sources
Related Research
The Terpene Evidence Base
This paper sits at the center of the terpene debate — between the theoretical framework of the entourage effect and the analytical reality of what cannabis actually contains.
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects
Russo (2011)
The theoretical framework: 8 terpenes mapped to cannabinoid synergies. Hanuš provides the analytical chemistry showing what's actually in the plant.
A tale of two cannabinoids: THC and CBD therapeutic rationale
Russo & Guy (2006)
The THC-CBD synergy paper — the strongest confirmed component of the entourage effect that terpenes are hypothesized to extend
2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor
Hanuš et al. (2001)
Hanuš's earlier analytical chemistry work — the same bench skills applied first to endocannabinoids, now to terpenes
Cannabinoid pharmacology: the first 66 years
Pertwee (2006)
The cannabinoid pharmacology that terpenes are hypothesized to interact with
What are the most common terpenes in cannabis?
Based on analysis of 108 cannabis chemotypes, beta-caryophyllene and beta-myrcene are the two most prevalent terpenes across the widest range of cultivars. Alpha-pinene, limonene, beta-pinene, linalool, and alpha-humulene are also common but more variable between strains. The relative proportions vary dramatically by cultivar, but caryophyllene and myrcene form the backbone of most cannabis terpene profiles.
Do terpenes actually change how cannabis affects you?
Probably, but the mechanism and magnitude are unclear. Beta-caryophyllene is the only terpene proven to directly bind a cannabinoid receptor (CB2). Other terpenes have documented pharmacological effects through non-cannabinoid mechanisms (serotonin receptors, GABA modulation, anti-inflammatory pathways). Whether these effects are meaningful at the concentrations inhaled from cannabis is debated — one major study found no terpene activity at CB1/CB2, while another found terpenes produced cannabinoid-like effects in mice. The honest answer: terpenes likely contribute something, but we can't quantify what yet.
Should I shop for cannabis by terpene profile?
Terpene data is useful for predicting aroma and flavor — that's well-established. Using terpene profiles to predict therapeutic effects or subjective experience is more speculative. THC content, the THC:CBD ratio, dose, and your individual biology are more established predictors. That said, if you notice you consistently enjoy products with certain terpene profiles, tracking that preference is reasonable consumer behavior. Just don't expect the precision that the marketing implies. For a full guide, see our article on terpenes explained.
What the researchers found
Systematic GC-MS analysis of 108 cannabis chemotypes revealed that beta-caryophyllene and beta-myrcene are the two most prevalent terpenes across the widest range of cultivars, appearing in the top 10 in over 80 samples each. Alpha-pinene, limonene, and linalool were also common but more variable. The authors reviewed pharmacological evidence for each major terpene and concluded that terpenes are likely therapeutically important but insufficiently studied in human clinical contexts.
Why it matters
Provides the first large-scale systematic characterization of what terpenes are actually present in cannabis across diverse cultivars. Bridges the gap between industry marketing claims about terpenes and analytical reality. The finding that beta-caryophyllene (a confirmed CB2 agonist) is the most prevalent terpene adds weight to the entourage effect hypothesis.
The numbers in context
108 chemotypes analyzed by GC-MS. Beta-caryophyllene and beta-myrcene most prevalent (top 10 in 80+ samples). Main terpenes ranged 8-35% of total terpene content in inflorescences. Some essential oils showed dominant terpenes exceeding 65% of volatile content.
How the study worked
Gas chromatography-mass spectrometry (GC-MS) analysis of 108 cannabis chemotypes — both inflorescences and essential oils. Terpene identification against known reference standards. Systematic literature review of pharmacological data for each identified terpene.
Who was studied
108 cannabis chemotypes (plant material analysis, not human subjects)
What this study cannot tell us
GC-MS provides relative percentages, not absolute quantities absorbed by users. The gap between 'present in the plant' and 'active in the body' is significant. Most pharmacological data comes from animal models or in vitro studies. No human clinical trial data on terpene-specific therapeutic effects from cannabis.
How to read the evidence
Strong analytical chemistry (GC-MS of 108 chemotypes is a large, rigorous dataset). Pharmacological review is comprehensive but relies primarily on animal and in vitro data. No human clinical evidence for terpene-specific therapeutic effects from cannabis. The paper is honest about this limitation.
When this study was published
Published in 2020, the same year as the Santiago/Finlay study finding no terpene activity at CB1/CB2. Together, these papers represent the analytical and pharmacological state of knowledge as of 2020.
The bigger picture
This paper provides the analytical foundation that the terpene marketing hype has been missing. The industry has been making claims about terpene effects without knowing what's consistently in the plant. Hanuš provided that data. The answer: caryophyllene and myrcene dominate, which is encouraging (caryophyllene is a confirmed CB2 agonist), but the gap between analytical presence and proven therapeutic effect remains wide.
Questions still open
- Are the terpene concentrations in cannabis sufficient to produce systemic pharmacological effects when inhaled? Does beta-caryophyllene's CB2 activity meaningfully contribute to cannabis's therapeutic effects at the concentrations found in typical cultivars? How much terpene variation matters for patient outcomes?
Common questions
Read the original research
Terpenes/Terpenoids in Cannabis: Are They Important?
Med Cannabis Cannabinoids
Medical Cannabis and Cannabinoids — a peer-reviewed journal from Karger Publishers dedicated to research on cannabis-based medicines and the endocannabinoid system.
Citation
Hanuš LO, Hod Y. (2020). Terpenes/Terpenoids in Cannabis: Are They Important?. Med Cannabis Cannabinoids. https://doi.org/10.1159/000509733